$4.440
-0.098 (-2.20%)At close
GTBP Comparative Benchmarking
In the context of the broader market, GTBP competes directly with industry leaders such as MBRX and LEXX. With a market capitalization of $7.99M, it holds a significant position in the sector. When comparing efficiency, GTBP's gross margin of N/A stands against MBRX's N/A and LEXX's 100.00%. Such benchmarking helps identify whether GT Biopharma Inc is trading at a premium or discount relative to its financial performance.
GT Biopharma Inc Financial Performance
The company reported a widening net loss of approximately $28.4 million for FY2025, up from a $13.2 million loss in FY2024, highlighting ongoing financial struggles. Additionally, the current ratio is low at 2.61, indicating potential liquidity concerns despite some improvement.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.